The global irritable bowel syndrome treatment market accounted for USD 1.65 billion in 2023 and is expected to reach at USD 4.74 billion by 2034 with a CAGR of 10.07% during the forecast period 2024-2034. The market will grow as a result of factors such as rising IBS prevalence, more awareness of the condition, the development of new treatments, an emphasis on personalized medicine, and emerging markets.
IBS is a widespread gastrointestinal ailment that impacts millions of individuals globally. Although the precise origin of IBS is unknown, several factors, including stress, gut bacteria, and genetics, are likely to be involved. The market for IBS treatments is mostly driven by the increasing prevalence of IBS. Personalized medicine is becoming more and more popular in the management of IBS. This indicates that physicians are customizing treatment regimens to meet the requirements of each patient. Personalized medicine has the potential to outperform conventional generic therapies. For instance, in February 2024 RedHill Biopharma Ltd. reported good outcomes from a Phase II clinical trial assessing a possible new treatment for IBS-D.
By type, the mixed-presentation IBS segment accounted for the highest revenue-grossing segment in the global irritable bowel syndrome treatment market in 2023 owing to the increased recognition of the complex nature of IBS symptoms and the need for versatile treatment options to address both diarrhea-predominant and constipation-predominant symptoms. For instance, in February 2022, Takeda revealed favorable topline findings from the Phase 2 Trial of TAK-954 for the treatment of constipation and IBS. Additionally, the IBS with constipation segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising demand for effective therapies targeting constipation symptoms and the development of novel drugs specifically tailored to address this subtype of IBS.
By product, the rifaximin segment accounted for the highest revenue-grossing segment in the global irritable bowel syndrome treatment market in 2023 owing to the growing adoption of rifaximin due to its effectiveness in treating IBS symptoms, particularly in patients with diarrhea-predominant IBS, and its favorable safety profile. For instance, RedHill Biopharma Ltd. reported positive results from a Phase II clinical trial evaluating a potential novel medication for IBS-D in February 2024. Additionally, the eluxadoline segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing acceptance of eluxadoline as a targeted therapy for managing symptoms of diarrhea-predominant IBS and its efficacy in reducing abdominal pain and improving bowel habits.
By Distribution Channel, the hospitals and pharmacies segment accounted for the highest revenue-grossing segment in the global irritable bowel syndrome treatment market in 2023 owing to the increased accessibility and availability of IBS treatments, coupled with the convenience of obtaining prescriptions and medications from these established healthcare settings. For instance, RedHill Biopharma Ltd. reported positive results from a Phase II clinical trial evaluating a potential treatment medication for IBS-D in February 2024. Additionally, the online pharmacies segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing consumer preference for convenient and discreet purchasing options, coupled with the expansion of online pharmacy platforms offering a wide range of IBS treatments and home delivery services.
North American region is anticipated to have the highest revenue share during the forecast period owing to the high prevalence of IBS, well-established healthcare infrastructure, increasing adoption of advanced treatment options, and favorable reimbursement policies in the North American region. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rising awareness about IBS, improving healthcare infrastructure, increasing disposable income, and a growing focus on gastrointestinal health in the Asia Pacific region. For instance, in February 2024 RedHill Biopharma Ltd. announced encouraging outcomes from a Phase II clinical trial assessing a possible therapeutic medicine for IBS-D.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
IBS is a widespread gastrointestinal ailment that impacts millions of individuals globally. Although the precise origin of IBS is unknown, several factors, including stress, gut bacteria, and genetics, are likely to be involved. The market for IBS treatments is mostly driven by the increasing prevalence of IBS. Personalized medicine is becoming more and more popular in the management of IBS. This indicates that physicians are customizing treatment regimens to meet the requirements of each patient. Personalized medicine has the potential to outperform conventional generic therapies. For instance, in February 2024 RedHill Biopharma Ltd. reported good outcomes from a Phase II clinical trial assessing a possible new treatment for IBS-D.
By type, the mixed-presentation IBS segment accounted for the highest revenue-grossing segment in the global irritable bowel syndrome treatment market in 2023 owing to the increased recognition of the complex nature of IBS symptoms and the need for versatile treatment options to address both diarrhea-predominant and constipation-predominant symptoms. For instance, in February 2022, Takeda revealed favorable topline findings from the Phase 2 Trial of TAK-954 for the treatment of constipation and IBS. Additionally, the IBS with constipation segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising demand for effective therapies targeting constipation symptoms and the development of novel drugs specifically tailored to address this subtype of IBS.
By product, the rifaximin segment accounted for the highest revenue-grossing segment in the global irritable bowel syndrome treatment market in 2023 owing to the growing adoption of rifaximin due to its effectiveness in treating IBS symptoms, particularly in patients with diarrhea-predominant IBS, and its favorable safety profile. For instance, RedHill Biopharma Ltd. reported positive results from a Phase II clinical trial evaluating a potential novel medication for IBS-D in February 2024. Additionally, the eluxadoline segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing acceptance of eluxadoline as a targeted therapy for managing symptoms of diarrhea-predominant IBS and its efficacy in reducing abdominal pain and improving bowel habits.
By Distribution Channel, the hospitals and pharmacies segment accounted for the highest revenue-grossing segment in the global irritable bowel syndrome treatment market in 2023 owing to the increased accessibility and availability of IBS treatments, coupled with the convenience of obtaining prescriptions and medications from these established healthcare settings. For instance, RedHill Biopharma Ltd. reported positive results from a Phase II clinical trial evaluating a potential treatment medication for IBS-D in February 2024. Additionally, the online pharmacies segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing consumer preference for convenient and discreet purchasing options, coupled with the expansion of online pharmacy platforms offering a wide range of IBS treatments and home delivery services.
North American region is anticipated to have the highest revenue share during the forecast period owing to the high prevalence of IBS, well-established healthcare infrastructure, increasing adoption of advanced treatment options, and favorable reimbursement policies in the North American region. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rising awareness about IBS, improving healthcare infrastructure, increasing disposable income, and a growing focus on gastrointestinal health in the Asia Pacific region. For instance, in February 2024 RedHill Biopharma Ltd. announced encouraging outcomes from a Phase II clinical trial assessing a possible therapeutic medicine for IBS-D.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Type, Product, and Distribution Channel
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement
Segmentation: Irritable Bowel Syndrome Treatment Market Report 2023 - 2034
Irritable Bowel Syndrome Treatment Market Analysis & Forecast by Type 2023 - 2034 (Revenue USD Bn)
- IBS with Diarrhea (IBS-D)
- IBS with Constipation (IBS-C)
- Mixed-presentation IBS (IBS-M)
Irritable Bowel Syndrome Treatment Market Analysis & Forecast by Product 2023 - 2034 (Revenue USD Bn)
- Rifaximin
- Eluxadoline
- Lubiprostone
- Linaclotide
- Others
Irritable Bowel Syndrome Treatment Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Bn)
- Hospitals Pharmacies
- Drug Stores & Retail Pharmacies
- Online Pharmacies
Irritable Bowel Syndrome Treatment Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Irritable Bowel Syndrome Type Market: Type Estimates & Trend Analysis
8. Irritable Bowel Syndrome Type Market: Product Estimates & Trend Analysis
9. Irritable Bowel Syndrome Type Market: Distribution Channel Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Irritable Bowel Syndrome Type Market
12. Europe Global Irritable Bowel Syndrome Type Market
13. Asia Pacific Global Irritable Bowel Syndrome Type Market
14. Latin America Global Irritable Bowel Syndrome Type Market
15. MEA Global Irritable Bowel Syndrome Type Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Allergan plc
- Takeda Pharmaceutical Company Limited
- Ironwood Pharmaceuticals Inc.
- Valeant Pharmaceuticals International Inc.
- Synergy Pharmaceuticals Inc.
- Salix Pharmaceuticals Inc.
- Ardelyx Inc.
- Astellas Pharma Inc.
- Lexicon Pharmaceuticals Inc.
- Norgine B.V.
- Sebela Pharmaceuticals Inc.
- RedHill Biopharma Ltd.
- Pfizer Inc.
- Probi AB
- Abbott Laboratories.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | October 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 1.65 Billion |
| Forecasted Market Value ( USD | $ 4.74 Billion |
| Compound Annual Growth Rate | 10.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
